 Rocio Pereira
Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adiponectin | 5 | 2016 | 244 | 1.290 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2026 | 2575 | 1.190 |
Why?
| | Cultural Diversity | 2 | 2025 | 87 | 1.020 |
Why?
| | Health Promotion | 3 | 2025 | 765 | 0.940 |
Why?
| | Community Health Workers | 1 | 2025 | 79 | 0.870 |
Why?
| | Public Policy | 1 | 2023 | 76 | 0.800 |
Why?
| | Prejudice | 1 | 2023 | 60 | 0.800 |
Why?
| | Minority Groups | 2 | 2024 | 279 | 0.760 |
Why?
| | Insulin Resistance | 7 | 2017 | 1234 | 0.750 |
Why?
| | Patient Care Team | 2 | 2025 | 690 | 0.740 |
Why?
| | Perception | 1 | 2025 | 378 | 0.720 |
Why?
| | Family | 1 | 2026 | 683 | 0.700 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2023 | 718 | 0.660 |
Why?
| | Blood Glucose | 5 | 2023 | 2316 | 0.520 |
Why?
| | Adipocytes | 3 | 2016 | 222 | 0.490 |
Why?
| | Attitude of Health Personnel | 1 | 2024 | 1207 | 0.470 |
Why?
| | Adiposity | 3 | 2015 | 532 | 0.460 |
Why?
| | Weight Reduction Programs | 1 | 2017 | 124 | 0.460 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2008 | 374 | 0.450 |
Why?
| | Colorado | 6 | 2026 | 4658 | 0.440 |
Why?
| | Mexican Americans | 1 | 2015 | 114 | 0.440 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2021 | 637 | 0.420 |
Why?
| | Qualitative Research | 3 | 2026 | 1563 | 0.400 |
Why?
| | Weight Loss | 5 | 2025 | 811 | 0.380 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 1089 | 0.370 |
Why?
| | Middle Aged | 20 | 2026 | 35342 | 0.350 |
Why?
| | Adult | 19 | 2026 | 40013 | 0.350 |
Why?
| | Medicare | 1 | 2017 | 811 | 0.350 |
Why?
| | Interviews as Topic | 2 | 2025 | 868 | 0.330 |
Why?
| | Postmenopause | 3 | 2017 | 377 | 0.330 |
Why?
| | Racism | 2 | 2024 | 147 | 0.330 |
Why?
| | Humans | 31 | 2026 | 143560 | 0.280 |
Why?
| | Diet | 1 | 2015 | 1290 | 0.270 |
Why?
| | Thiazolidinediones | 1 | 2008 | 136 | 0.270 |
Why?
| | Female | 23 | 2026 | 77251 | 0.250 |
Why?
| | Subcutaneous Fat | 2 | 2017 | 82 | 0.250 |
Why?
| | Male | 18 | 2026 | 71500 | 0.240 |
Why?
| | Narration | 1 | 2026 | 68 | 0.220 |
Why?
| | Inpatients | 2 | 2023 | 521 | 0.220 |
Why?
| | Supreme Court Decisions | 1 | 2023 | 12 | 0.210 |
Why?
| | United States | 6 | 2023 | 15553 | 0.210 |
Why?
| | Community Health Centers | 1 | 2024 | 63 | 0.210 |
Why?
| | Reminder Systems | 1 | 2026 | 175 | 0.210 |
Why?
| | Text Messaging | 2 | 2016 | 182 | 0.200 |
Why?
| | Estradiol | 2 | 2017 | 525 | 0.200 |
Why?
| | Prediabetic State | 2 | 2016 | 253 | 0.200 |
Why?
| | Food Assistance | 1 | 2023 | 33 | 0.190 |
Why?
| | Health Behavior | 2 | 2026 | 789 | 0.190 |
Why?
| | Safety-net Providers | 1 | 2023 | 124 | 0.180 |
Why?
| | Body Mass Index | 5 | 2025 | 2429 | 0.180 |
Why?
| | Social Support | 1 | 2026 | 635 | 0.180 |
Why?
| | Program Evaluation | 1 | 2025 | 937 | 0.170 |
Why?
| | Influenza Vaccines | 1 | 2026 | 553 | 0.160 |
Why?
| | Estrogen Receptor beta | 2 | 2017 | 43 | 0.160 |
Why?
| | Postpartum Period | 1 | 2023 | 352 | 0.160 |
Why?
| | Hypoglycemic Agents | 2 | 2012 | 1394 | 0.160 |
Why?
| | Obesity | 3 | 2023 | 3041 | 0.160 |
Why?
| | Influenza, Human | 1 | 2026 | 636 | 0.150 |
Why?
| | Vaccination | 2 | 2026 | 1484 | 0.150 |
Why?
| | Estrogen Receptor alpha | 2 | 2017 | 147 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2023 | 1051 | 0.140 |
Why?
| | Medicaid | 1 | 2023 | 460 | 0.140 |
Why?
| | Cost of Illness | 1 | 2021 | 319 | 0.140 |
Why?
| | Overweight | 1 | 2023 | 598 | 0.140 |
Why?
| | Dietary Fats | 2 | 2018 | 304 | 0.140 |
Why?
| | Insulin | 4 | 2012 | 2497 | 0.140 |
Why?
| | Delivery of Health Care | 2 | 2024 | 954 | 0.140 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2017 | 40 | 0.130 |
Why?
| | Sleep Wake Disorders | 1 | 2021 | 315 | 0.130 |
Why?
| | 3T3-L1 Cells | 2 | 2008 | 36 | 0.130 |
Why?
| | Health Personnel | 1 | 2024 | 736 | 0.130 |
Why?
| | Body Fat Distribution | 1 | 2017 | 47 | 0.130 |
Why?
| | Caregivers | 1 | 2026 | 970 | 0.130 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2026 | 1413 | 0.130 |
Why?
| | Age Factors | 2 | 2017 | 3328 | 0.130 |
Why?
| | Critical Illness | 1 | 2023 | 869 | 0.130 |
Why?
| | Pericardium | 1 | 2017 | 61 | 0.130 |
Why?
| | Cross-Sectional Studies | 4 | 2021 | 5743 | 0.130 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2017 | 128 | 0.120 |
Why?
| | Human Development | 1 | 2016 | 22 | 0.120 |
Why?
| | Exercise | 2 | 2025 | 2151 | 0.120 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2017 | 3832 | 0.120 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2017 | 102 | 0.120 |
Why?
| | Organ Specificity | 1 | 2016 | 311 | 0.120 |
Why?
| | Diet Surveys | 1 | 2015 | 93 | 0.120 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3380 | 0.110 |
Why?
| | Insurance Coverage | 1 | 2017 | 240 | 0.110 |
Why?
| | Puberty | 1 | 2016 | 158 | 0.110 |
Why?
| | Healthy Volunteers | 1 | 2015 | 213 | 0.110 |
Why?
| | Adipose Tissue | 2 | 2017 | 654 | 0.110 |
Why?
| | Weight Gain | 1 | 2018 | 550 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2017 | 425 | 0.110 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 142 | 0.110 |
Why?
| | Sex Factors | 2 | 2017 | 2092 | 0.100 |
Why?
| | Cohort Studies | 2 | 2017 | 5891 | 0.100 |
Why?
| | Language | 1 | 2017 | 323 | 0.100 |
Why?
| | Energy Metabolism | 2 | 2018 | 939 | 0.100 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 1324 | 0.100 |
Why?
| | Pilot Projects | 3 | 2026 | 1838 | 0.090 |
Why?
| | Stem Cells | 1 | 2016 | 619 | 0.090 |
Why?
| | Signal Transduction | 1 | 2005 | 5214 | 0.090 |
Why?
| | Logistic Models | 1 | 2017 | 2107 | 0.090 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2012 | 158 | 0.090 |
Why?
| | Molecular Weight | 1 | 2012 | 327 | 0.090 |
Why?
| | Abdominal Fat | 1 | 2012 | 50 | 0.090 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 198 | 0.090 |
Why?
| | Self Report | 1 | 2015 | 877 | 0.090 |
Why?
| | Vascular Stiffness | 1 | 2015 | 463 | 0.080 |
Why?
| | Patient Admission | 1 | 2012 | 203 | 0.080 |
Why?
| | Insulin Antagonists | 1 | 2008 | 6 | 0.070 |
Why?
| | Cell Differentiation | 1 | 2016 | 2020 | 0.070 |
Why?
| | Androstadienes | 1 | 2008 | 74 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2023 | 16741 | 0.070 |
Why?
| | Young Adult | 4 | 2023 | 13972 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1787 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2008 | 790 | 0.060 |
Why?
| | Hypertension | 1 | 2015 | 1260 | 0.060 |
Why?
| | Sex Characteristics | 1 | 2012 | 793 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1223 | 0.060 |
Why?
| | Aged | 5 | 2017 | 25322 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 151 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 183 | 0.060 |
Why?
| | Diet, Reducing | 1 | 2005 | 90 | 0.050 |
Why?
| | Biomarkers | 1 | 2015 | 4241 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2056 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2016 | 2852 | 0.050 |
Why?
| | Cell Line | 1 | 2008 | 2897 | 0.050 |
Why?
| | Cystic Fibrosis | 1 | 2012 | 1142 | 0.050 |
Why?
| | Phobic Disorders | 1 | 2022 | 36 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 2008 | 1511 | 0.040 |
Why?
| | Policy | 1 | 2022 | 150 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2008 | 4182 | 0.040 |
Why?
| | Smoking Cessation | 1 | 2004 | 435 | 0.040 |
Why?
| | Mice | 2 | 2008 | 18378 | 0.040 |
Why?
| | Adolescent | 2 | 2016 | 22481 | 0.040 |
Why?
| | Poverty | 1 | 2023 | 528 | 0.040 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2017 | 21 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5308 | 0.030 |
Why?
| | Placebos | 1 | 2017 | 195 | 0.030 |
Why?
| | Cell Size | 1 | 2016 | 91 | 0.030 |
Why?
| | Adipogenesis | 1 | 2016 | 57 | 0.030 |
Why?
| | Intra-Abdominal Fat | 1 | 2017 | 98 | 0.030 |
Why?
| | Cell Phone | 1 | 2016 | 82 | 0.030 |
Why?
| | Hospitalization | 2 | 2022 | 2313 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2022 | 691 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2017 | 583 | 0.030 |
Why?
| | Animals | 2 | 2008 | 38010 | 0.030 |
Why?
| | Sleep | 1 | 2021 | 889 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2016 | 11365 | 0.030 |
Why?
| | Likelihood Functions | 1 | 2012 | 144 | 0.020 |
Why?
| | Texas | 1 | 2012 | 273 | 0.020 |
Why?
| | Infant | 1 | 2026 | 9981 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1984 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 2017 | 0.020 |
Why?
| | Child, Preschool | 1 | 2026 | 11737 | 0.020 |
Why?
| | Blood Pressure | 1 | 2017 | 1755 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2012 | 220 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3625 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2016 | 2542 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 6025 | 0.020 |
Why?
| | Apoptosis | 1 | 2016 | 2519 | 0.020 |
Why?
| | Insulin Infusion Systems | 1 | 2012 | 482 | 0.020 |
Why?
| | Lipids | 1 | 2012 | 704 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2621 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1877 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7031 | 0.020 |
Why?
| | Basal Metabolism | 1 | 2005 | 64 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2177 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2005 | 152 | 0.010 |
Why?
| | Hospitals, Urban | 1 | 2004 | 137 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3211 | 0.010 |
Why?
| | Fasting | 1 | 2005 | 284 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 7899 | 0.010 |
Why?
| | Energy Intake | 1 | 2005 | 513 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2779 | 0.010 |
Why?
| | Urban Population | 1 | 2004 | 491 | 0.010 |
Why?
| | Child | 1 | 2016 | 22725 | 0.010 |
Why?
|
|
Pereira's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|